April 11, 2019
FDA to require label changes on how to safely decrease opioids in physically dependent patients
Editor's Note
The Food & Drug Administration (FDA) on April 9 issued a Drug Safety Announcement saying it has received reports of serious harm in patients who are physically dependent on opioid pain medications and suddenly have them discontinued or rapidly decreased.
Because of these reports, the FDA is requiring changes to prescribing information, which will provide expanded guidance on how to safely decrease the dose in patients when the dose is to be decreased or the medication is to be discontinued.
Free Daily News
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO
- CMS final rule for CY 2025: Key updates impacting Medicare payments, quality programs
- GAO urges HHS to strengthen cybersecurity oversight
- Study: GLP-1s reduce TKA complications for non-diabetic patients with obesity
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement